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Trials, The ASCO recommendations about SNB, The Canadian 
SN FNAC and German SENTINA, The MD Anderson trials, and 
the ACOSOG Z 1071 and AO11202 ALLIANCE (NCTO 1901094) 
 
Results: For patients treated with NAC, patients with 
advanced stages (T3-4 /N2-3) should receive RT after 
independent NAC response. In early stages, it would be 
reasonable to receive treatment if there were residual 
disease; if doubts exist in cases of pRC, such cases should be 
assessed individually. It seems clear that patients with 
clinical regional involvement who present affectations of the 
lymph nodes following NAC will benefit from locoregional RT, 
but it is less clear in those who are pN0 following the NAC, as 
their risk of LRR is low.  
 
Conclusion: The benefit of locoregional RT is not clear in 
patients with pN0 following the NAC The ongoing NSABPB-51 
/RTOG1304 (NRG 9353) study has been designed to answer 
this question. We must wait for the results of this important 
trial. Until these results, we must follow the 
recommendations previously prescribed. 
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Purpose or Objective: To present the clinical results of ABPI 
using 3D-CRT and IG-IMRT following breast-conserving surgery 
(BCS) for early-stage breast cancer. 
 
Material and Methods: Between 2006 and 2014, 104 low risk 
breast cancer patients were treated with postoperative APBI 
given by means of 3D-CRT (n=44) using 3-5 non-coplanar, 
izocentric wedged fields, or IG-IMRT (n=60) technique using 
KVCBCT guidance for each fractions. The total dose of APBI 
was 36.9 Gy (9 x 4.1 Gy) using twice-a-day fractionation for 5 
consecutive days. Survival results, side effects, and cosmetic 
results were assessed. 
 
Results: At a median follow-up of 48 months (range: 25-112) 
one (0.9%) local recurrence was observed. Two patients 
(1.9%) died of internal disease. One (0.9%) contralateral 
recurrence and three (2.8%) secondary tumours were 
observed. Neither regional nor distant failure was detected. 
Acute side effects included grade 1 (G1) and G2 erythema in 
54 (51.9%) and 2 (1.9%), G1 parenchymal induration in 43 
(41.3%), G1 and G2 pain in 26 (25%) and 2 (1.9%) patients. No 
≥G3 or higher acute side effect occurred. Late side effects 
included G1 telangiectasia in 10 (9.6%) G1, G2, and G3 
fibrosis in 26 (25%), 3 (2.8%) and 1 (0.9%) patients 
respectively. Asymptomatic (G1) fat necrosis occurred in 8 
(7.7%) patients. The rate of excellent/good and fair/poor 
cosmetic results was 96 (92.3%), 8 (7.7%) respectively.  
 
Conclusion: Both 3D-CRT and IG-IMRT for delivery the ABPI is 
feasible and the 4 years clinical results and toxicity profile is 
comparable to other results using multicatheter APBI 
brachytherapy.  
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Purpose or Objective: Radiation and anthracyclines are 
known to induce cardiac damage. Despite the use of 3D 
planning the heart is still irradiated with non-negligible 
doses, therefore this problem needs further investigation. We 
perform an analysis of cardiac function in the left sided 
breast cancer survivors. Patients were treated with surgery 
alone (S), additional radiation (RT), additional anthracycline 
based chemotherapy (A) or both (RA).  
 
Material and Methods: A total of 140 patients were 
subjected to cardiological evaluation more than 8 years after 
primary treatment. We performed ECG and ECHO (in a part 
of patients we also had an ECG and ECHO performed before 
surgery), blood tests, chest X-ray. We also collected 
additional relevant information on patients (history, 
comorbidities, current treatment, etc.). Distribution of 
patients was as follows 50% RA arm, 18% S, 8% RT, 24% A. The 
mean time from the beginning of the treatment to 
examination was 12.2 years (8-15.9) in S, 11.7 (8-16.9) in A, 
10.7 (8-15.3) in RT, 10.1 (8.1-14.5) in RA. The majority of 
patients were treated with amputation (74%), the remaining 
with BCT. In chemotherapy arms 47% were treated with FAC, 
31% with CAF, 19% with AC, and 3% with TE. Hormonal 
treatment was given to 64% of patients, in the majority of 
them it was Tamoxifen-based. Radiotherapy dose varied 
between 50 and 70 Gy. 
 
Results: There was no significant difference in ejection 
fraction (EF) between the groups: median 56 (47-65) in S, 50 
(25-65) in A, 55 (47-62) in RT and 54 (35-67) in RA. Other 
evaluated parameters like size of the right and left ventricle, 
left atrium, thickness of septum and posterior wall also did 
not differ between groups. In the whole group in 21% of 
patients we observed chronic cardiac insufficiency. In 58% of 
patients there were other cardiovascular disorders as 
hypertension, hypercholesterolemia, atherosclerosis, 
arrhythmias, and valvular disorders. Only in one patient 
treated with radiation and chemotherapy we found impaired 
heart function without other additional causes.  
 
Conclusion: In the current series no unequivocal association 
between treatment regimen and long-term cardiac 
dysfunction could be found. Further studies in a well-
balanced patient population are needed to elucidate the 
impact of contemporary anthracycline-based systemic 
treatment and modern irradiation techniques on cardiac 
outcome.  
The research received funding from National Science Center 
Poland under grant no. N N 402 685640 
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Purpose or Objective: Incidental radiation dose to the heart 
and lung during left breast radiation therapy (RT) has been 
associated with an increased risk of cardiopulmonary 
morbidity especially in patients treated with antracyclin as 
neoadjuvant/adjuvant chemotherapy schedules after surgery. 
We conducted two different dosimetric analyses (by NTCP 
and Bio-DVH) to determine if left breast RT with the Active 
Breathing Coordinator (ABC) can reduce heart/left anterior 
descending artery (LAD) and lung dose without target 
coverage impairment. 
 
Material and Methods: Patients with stages 0-III left breast 
cancer (LBC) were enrolled and underwent simulation with 
both free breathing (FB) and ABC for comparison of 
dosimetry. ABC was used during the patient's RT course if the 
heart exposition was V(30) ≥ 12%. The prescription dose was 
50 Gy plus a boost in 88% and 2,75 Gy up to 44 Gy plus a 
boost in 22%. The primary endpoint was the magnitude of 
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heart reduction dose when comparing ABC to FB. Analysis was 
performed with BIOPLAN (BiOlogical evaluation of PLANs) PC 
based user-friendly software (evaluation of Dmax, Dmin, 
Dmean) and home-made Planning Reporting Orienteering 
(PRO)-DVH software. PRODVH produced Bio-DVH (Equivalent 
Dose Volume histograms for 25 fractions) that allowed the 
comparison regardless of the treatment schedule and that 
were used to calculate the average DVH for each set up. 
Secondary endpoints included dose reduction to the lung and 
procedural success rate. 
 
Results: Between May 2012 to February 2015, 50 patients 
with LBC are selected for receiving RT using ABC after both 
FB and ABC simulation. Procedural success was good, all 
patients have sufficient compliance and are been selected for 
this procedure. The primary endpoint was achieved: use of 
ABC reduced LAD/heart exposition (p < 0.01 T-student test). 
There was no significant difference between the free-
breathing and moderate deep inspiration breath-holding in 
the target volume coverage. The volume of the ipsilateral 
lung in the free-breathing technique was smaller than the 
moderate deep inspiration breath-holding techniques. All 
these data were confirmed with both software. 
 
Conclusion: ABC was well tolerated and significantly reduced 
heart/LAD dose without impairment in target volume 
coverage. No difference was find in lung dose reduction. Use 
of the ABC device during RT should be considered to reduce 
the risk of ischemic heart disease in populations at risk. 
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Purpose or Objective: Proper multi-atlas automated 
delineation can streamline clinical routine only when the 
proposed volume determination reasonably approximates the 
manual delineation. In this investigation we aimed to 
evaluate the automatic atlas-based segmentation of 
supraclavicular and level 3 lymph nodes for loco-regional 
irradiation of breast cancer. Further analysis were performed 
on the final plan’s dose coverage to the automated clinical 
target volume. 
 
Material and Methods: Between June and September 2015 
five consecutive breast cancer patients with clinical 
indication for loco-regional irradiation were selected. Pre-
defined breast delineation atlas of Mirada RTx (version 1.6.2, 
Mirada Medical, Oxford, United Kingdom) software were used 
to generate automated clinical target volumes (CTVauto) 
including the supraclavicular and the axillary level 3 lymph 
nodes. Responsible radiation oncologist delineated the 
reference CTV (CTVref) for each individual patients as well. 
Comparison metrics of Dice similarity (DI) and commonly 
contoured volume (CCV) were used. Furthermore the 
CTVauto was expanded with 1,2,3,4 and 5 mm uniform 
margin consecutively followed by an evaluation of the 
volumetric coverage of CTVref. Finally clinical plans were 
created expanding CTVref with 5 mm uniform margin using 
either direct antero-posterior beam or multi-beam IMRT. 
Dose coverage of the 95% of prescribed dose (V95) were 
compared for both CTVs. 
 
Results: The average CTVref was 35.1 cc (Standard deviation 
= 10.2), while for the CTVauto 42.1 cc (SD = 12.1). Mean DI 
and CCV were 0.73 (SD: 0.26) and 0.72 (SD: 0.28) 
respectively. Expanding the CTVauto up to 5 mm in 1 mm 
increments covered the CTVref with 53.9%, 77.9%, 88.1%, 
90.9% , 92.7% and 95.7% respectively. (Figure 1). For two 
patients single direct ante-posterior (AP) beam were used for 
the loco-regional treatment, while for the other three cases 
6 beam IMRT were used. Average V95% dose coverage of 
CTVref was 98.5% (SD: 3.0) which lowered to 92.0% (SD: 9.1%) 
for CTVauto. For the two patient with single AP field the 
CTVref were 93.0% and 99.5%, which dropped to 79.8% and 
99.4% for CTVauto. The multi-beam IMRT cases showed 100%, 
99.9% and 99.8% CTVref_V95 and 100%, 88.5% and 94.0% 
CTVauto_V95. 
 
 
 
Conclusion: CTV delineation using an atlas-based auto-
segmentation shows promising results even in a small 
complicated volume delineation such as the loco-regional 
lymph nodes of breast. Further improvement of the 
delineation accuracy is expected by adding more cases to the 
initial multi-atlas (with 3 provided cases). 
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Purpose or Objective: Locally advanced breast cancer 
(LABC), clinically classified as cT4, is mostly identified in 
elderly patients, typically featuring unfavorable prognosis. It 
is usually associated with ulceration, bleeding and local pain, 
with prolonged course. Radiation therapy (RT) shows an 
important role in local control and symptomatic control. 
Hypofractionation radiotherapy scheme, with a dose of 13 Gy 
in two fractions with an interval of 48 hours (also known as 
RT-FLASH), allows acceptable results. With this study we aim 
to evaluate the response of the patients treated with RT-
FLASH. 
 
Material and Methods: LABC patients treated from 2001 to 
2015 with RT-FLASH were retrospectively included. Local 
response was clinically assessed. Kaplan-Meier method was 
used for locoregional progression-free survival (LPFS) and 
overall survival (OS) analysis. Type I error of 0.05. 
 
Results: 63 patients were included, with a median age of 78 
years (39-92 years), 61.9% with Karnofsky ≤80% and median 
progression time of 13.5 months (2-180 months). Carcinoma 
not otherwise specified (NOS) was the most common 
histological type (84.1%), with estrogen receptor-positive in 
71.4%. Most of the tumors were cT4b (50.8%) and cT4c 
(36.5%) with cN+ in 60.3% and cM1 in 44.4%. At the initial 
evaluation 46.0% had bleeding injuries. Two RT-FLASH were 
performed in 65.1% of the patients. During treatment there 
was no record of toxicity. There was reduction of bleeding 
(81.5%), size (69.8%) and ulceration (39.6%). Surgical 
conditions were acquired in 23.8% of the patients. Patients 
cM1 received chemotherapy more often than cM0 (57.7% vs. 
17.6%; p=0.001). Of the 63.9% patients that received 
hormone therapy (HT), 77.5% had 2 RT-FLASH (p=0.002 vs. 
non-HT), with a greater dimensional reduction in patients 
undergoing HT (81.1% vs 43, 8%, p = 0.010). LPFS at 2 and 5 
years was 76.6% and 66.1%, respectively. The 2-year OS was 
39.7% and 5-year OS was 19.5%, higher in cM0 patients 
(p<0.001), patients subjected to 2 RT- FLASH (p=0.003), or 
under HT (p=0.001). Multivariate analysis showed significant 
